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Background: Diabetes, a highly prevalent, chronic disease, is associated with increasing frailty and functional
decline in older people, with concomitant personal, social, and public health implications. We describe the rationale
and methods of the multi-modal intervention in diabetes in frailty (MID-Frail) study.
Methods/Design: The MID-Frail study is an open, randomised, multicentre study, with random allocation by
clusters (each trial site) to a usual care group or an intervention group. A total of 1,718 subjects will be randomised
with each site enrolling on average 14 or 15 subjects. The primary objective of the study is to evaluate, in
comparison with usual clinical practice, the effectiveness of a multi-modal intervention (specific clinical targets,
education, diet, and resistance training exercise) in frail and pre-frail subjects aged ≥70 years with type 2 diabetes in
terms of the difference in function 2 years post-randomisation. Difference in function will be measured by changes
in a summary ordinal score on the short physical performance battery (SPPB) of at least one point. Secondary
outcomes include daily activities, economic evaluation, and quality of life.
Discussion: The MID-Frail study will provide evidence on the clinical, functional, social, and economic impact of a
multi-modal approach in frail and pre-frail older people with type 2 diabetes.
Trial registration: ClinicalTrials.gov: NCT01654341.
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Diabetes has a high prevalence in ageing populations, af-
fecting approximately 20% of people aged 70 years or
over. It is anticipated that by 2050 the number of cases
of diabetes will have increased by fourfold in people older
than 70 years [1]. Diabetes is associated with increasing
frailty and functional decline in older people [2]. Frailty is
defined as a clinical syndrome in which three or more of
the following criteria are present: unintentional weight* Correspondence: alan.sinclair@beds.ac.uk
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distribution, and reproduction in any mediumloss (≥4.5 kg in past year), self-reported exhaustion, weak-
ness (grip strength), slow walking speed, and low physical
activity [3].
Diabetes has serious personal and social consequences,
and is a significant public health burden in terms of rising
health care costs; in Spain, annual direct health care costs
have been estimated at 2.5 billion euros [4]. In recent
studies of older people, up to 28% of those with diabetes
required some help with activities of daily living, com-
pared with 16% of those without the condition [5]. This
functional decline can be explained in only half of the
cases by the classical complications of the disease, such as
coronary artery disease, stroke, and peripheral vasculard Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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terioration of skeletal muscle, increased co-morbidities,
and adverse effects of overmedication associated with dia-
betes, results in many older frail people becoming more
disabled, with an impaired quality of life associated with
increased use of health care resources [6-8].
There is a marked lack of intervention studies that
aim to reduce functional decline and improve quality of
life in older people with diabetes and until relatively re-
cently, most of the clinical guidelines for treating type 2
diabetes were of limited use in these subjects. A focus
on improvements in function and well-being may be fun-
damentally of more clinical benefit in older frail people
with diabetes than attention to metabolic control alone
[9]. In older adults and frail individuals, resistance training
is now considered to be an important component of
diabetes management and prevention, mainly through
increasing muscle mass, strength, and power [10]. This
leads, in turn, to increased mobility and a decreased risk
of falling [11]. In addition, resistance training has been
proven to improve insulin sensitivity and fasting gly-
caemia, and to decrease abdominal fat in older people
with type 2 diabetes [10]. It has been previously shown
that intensive glucose lowering therapy (targeting a gly-
cated haemoglobin level below 6.0%) in patients with type
2 diabetes was associated with a reduction in 5-year non-
fatal myocardial infarction but increased 5-year mortality
[12,13]. More recently, it was reported that an intensive
lifestyle intervention focusing on weight loss in overweight
or obese adults with type 2 diabetes led to improvements
in glycaemic control, blood pressure, high-density lipo-
protein (HDL)-cholesterol, and triglycerides [14]. How-
ever, the intervention failed to reduce the incidence of
cardiovascular events [15]. These observations provide
sufficient motivation for evaluating non-metabolic con-
trol as an alternative (and complementary) way of im-
proving clinical outcome.
The long-term impact of diabetes in an ageing popula-
tion results in substantial health care expenditure. This
further emphasises the potential value of an intervention
that can prevent or delay the onset of diabetes-associated
frailty. The multi-modal intervention in diabetes in frailty
(MID-Frail) study focuses on the use of interventions de-
signed to improve functional status and enhance quality
of life by acting on the mechanisms involved in frailty and
its progression to adverse outcomes [16]. The MID-Frail
study brings together 16 partners from seven countries in
the European Union (EU) and will run for 4 years, with
the intervention lasting 2 years. The primary objective of
the MID-Frail study is to evaluate, in comparison with
usual clinical practice, the effectiveness of a multi-modal
intervention (specific clinical targets, education, diet, and
exercise) in frail and pre-frail subjects aged ≥70 years with
type 2 diabetes in terms of the difference in function 2years post-randomisation. Difference in function will be
measured by changes in summary ordinal score on the
short physical performance battery (SPPB) of at least
one point.
Methods/design
Subjects
Inclusion criteria
Subjects are eligible to enter the study if all of the fol-
lowing apply:
1) The subject is willing and able to give written
informed consent for participation in the study.
2) The subject is aged 70 years or older, with a
diagnosis of type 2 diabetes for at least 2 years.
3) The subject fulfils the Fried’s criteria for frail or
pre-frail individuals (Table 1).
4) The caregiver has agreed to participate in the study
and to give informed consent for participation in the
carer burden part of the study. If the caregiver does
not agree, the subject may continue to participate in
the study, but information about caregiver burden
will not be collected.
Fried’s criteria for frailty were chosen as they are easy
to implement and allow the selection of subjects who
are not dependent (moderately or highly). In addition,
these criteria should avoid selection bias and prevent the
enrolment of a high percentage of subjects with disabil-
ities at baseline.
Exclusion criteria
Subjects cannot enter the study if any of the following
apply:
1) Barthel score lower than 60 points [17].
2) Inability to complete the SPPB (total score = 0)
(Figure 1) [18].
3) Mini Mental State Examination (MMSE) score of
less than 20 points [19].
4) Subject is unwilling or unable to consent or unable
to participate safely in the intervention programme.
5) Previous history of myocardial infarction within 6
months, unstable angina, or congestive heart failure
at stage III to IV of the New York Heart Association
(NYHA) classification [20].
6) The subject is clinically unstable in the clinical
judgment of the investigator.
7) Terminal illness (life expectancy <6 months).
8) Any other condition that, in the clinical judgment of
the investigator, means that it would not be in the
subject’s best interests to enter the study.
9) Concurrent participation in a clinical trial or any
other investigational study.
Table 1 Fried’s criteria for study inclusion
Criterion Definition
1. Weight
loss
Unintentional weight loss of 4.5 kg during the
past year
2. Exhaustion Using the responses (yes/no) to two statements on
the CES-D scale
3. Physical
activity
Is the weekly physical activity of the subject lower
or equal to (yes/no):
men: <383 kcal per week (walking: <2.5 hours per week)
women: <270 kcal per week (walking <2 hours per week)
4. Slowness Assessed by walk time and stratified by gender
and height
5. Weakness Assessed by grip strength and stratified by gender
and BMI
Frailty is indicated by satisfying three or more of the criteria; pre-frailty is
indicated by satisfying one or two of the criteria [3]. BMI, body mass index;
CES-D, Center for Epidemiologic Studies Depression.
Figure 1 The short physical performance battery (SPPB) [21]. Reprinte
Dufour AB and Hannan MT, Functional foot symmetry and its relation to lo
Foot Study, pp. 1796–1802, Copyright 2012, with permission from Elsevier.
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tional ethics committees in Spain (see further details in
Additional file 1). The study will be carried out in ac-
cordance with Good Clinical Practice, applicable local
regulatory requirements, and the guiding principles of
the Declaration of Helsinki.
Study design
This is an open, randomised, multicentre study, with
random allocation by clusters (each trial site) to a usual
care group or an intervention group (Figure 2). Each site
will enroll on average 14 or 15 subjects. National research
centres in Belgium, Czech Republic, Italy, and Germany
(one each) and in France, United Kingdom, and Spain
(two each) will each be responsible for 11 or 12 sites. Each
site will be monitored to ensure full adherence to thed from Journal of Biomechanics, Vol. 45, Riskowski JL, Hagedorn TJ,
wer extremity physical performance in older adults: the Framingham
Figure 2 Detailed study flowchart.
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adaptive monitoring strategy has been adopted in which
some sites will be monitored remotely. The study will
evaluate the intervention through the difference in func-
tioning between intervention and usual care groups; an
economic evaluation of the intervention and of quality of
life will also be carried out.Randomisation
Before randomisation, each trial site will identify and make
a list of 50 to 75 potential subjects. Identifying individuals
for recruitment before randomisation will help to avoid
subject selection bias [22]. Once this list is complete, the
investigator will have 1 month to obtain signed informed
consent from at least seven subjects (roughly half of the
site target size) on that list. Then, the site will be rando-
mised and exercise machines delivered. Randomisation
will be performed centrally by onmedic (Barcelona, Spain)
in collaboration with Cardiff University (Cardiff, UK).Intervention group
The study intervention consists of a multi-modal
programme comprising glycaemia and blood pressure
monitoring to reach pre-defined targets, a 16-week re-
sistance exercise programme based on leg press and leg
extension exercises (Additional file 2), and a nutritional
and educational programme. The exercise and the nu-
tritional and educational programmes will be run at the
study site at the beginning of year 1 and repeated at the
beginning of year 2. All subjects in this intervention
group will follow the multi-modal programme.Glycaemia and blood pressure monitoring The targets
for glycaemia and blood pressure control will be pre-
defined; however, the treatment required to achieve
them will not be pre-defined. Treatment protocols at
each site will be used to ensure that target values are
reached within 6 months of enrolment. There will be no
target for cholesterol or its fractions and there are no
specific recommendations for the use of aspirin. The tar-
get for glycaemia will be: optimal glycated haemoglobin
in the range of 7 to 8% (53 to 64 mmol/mol); the target
for blood pressure will be <150/90 mmHg.Exercise programme Subjects will undergo 2 weeks of
pre-training assessment before the exercise programme
begins. They will be familiarised with the exercises through
several submaximal and maximal performances, using
one-repetition maximum (1RM), and baseline measure-
ments will be taken. In all tests of exercise performance,
subjects will be encouraged verbally to perform each test
action as forcefully and as rapidly as possible.Exercise methodology The exercise programme used in
the MID-Frail study will be similar to one described pre-
viously [10,23]. The subjects will be asked to report to
the training facility on 2 days each week; each session
will last from 20 to 30 minutes. Training sessions will be
separated by a minimum of 2 days. Subjects will under-
take supervised resistance exercise for 16 weeks starting
at week 2 (baseline) and the assessments carried out at
baseline will be repeated in week 6, week 10, and week
18. Each training session will include two exercises for
the leg extensor and knee extensor muscles. Only resis-
tance machines will be used throughout the training
period (Exercycle, Exercycle S.L., Alava, Spain). For the
first 8 weeks of the training period, subjects will train
with loads of 40 to 60% of the individual 1RM, 8 to 12
repetitions per set, and 2 to 3 sets. For the last 8 weeks
of the training period, the loads will be 70 to 80% of the
maximum, 4 to 6 repetitions per set (higher loads), and 3
to 4 sets.
Nutritional and educational programme The MID-
Frail nutritional and educational programme is aimed
specifically at older people with diabetes and is derived
from a published programme for this particular popula-
tion [24]. The programme consists of sessions that aim
to increase the subject’s knowledge and understanding
of diabetes, to develop practical skills in diabetes self-
management, and to enhance the likelihood of improved
and safe control of glycaemia [25].
Each subject will undergo pre-trial assessment of nu-
tritional status and any requirement for weight reduction
or weight gain and the need for diet modification. There-
after, the intervention consists of clinician-moderated ses-
sions in a clinic or general practitioner surgery with small
groups of four to eight subjects. Seven separate 45-minute
sessions will be delivered, with two each week for 3 to 4
weeks; the sessions will be held on the same day as the
exercise sessions.
Usual care group
Subjects in the usual care group will receive the routine
care a subject with diabetes would normally be expected
to receive from his/her local health care system, includ-
ing his/her general practitioner.
Outcome measures
The primary outcome measure is the incidence of func-
tional impairment as measured by the difference in function
after 2 years of follow-up between intervention and usual
care groups, assessed by changes in summary ordinal score
on the SPPB test ≥1. Data from a previous study have
shown that one point is the minimum change in the SPPB
test that can be considered clinically significant [26]. Sec-
ondary outcome measures are listed in Table 2.
Table 2 Primary and secondary outcome measures
Outcome measure Definition
Primary The difference in function after 2 years of follow-up between intervention and usual care groups, according to changes in
summary ordinal score on the SPPB test ≥1 [26].
Secondary a) Barthel ADL index [13] and b) Lawton IADL scale [27].
c) Quality of life, as measured by using the EuroQoL index, EQ-5D-5 L [28].
d) Economic costs/health care expenditure due to diabetes and its impact on disability and quality of life, using an economic
model embracing the direct health-related costs (in-subject, out-subject, pharmaceutical), formal care costs (home care,
respite care, day centres), and the informal care costs (carer).
e) Episodes of symptomatic hypoglycaemia (that is, a recorded blood sugar <4 mmol/L, or symptoms or signs attributed to low
blood sugar and responding to appropriate treatment).
f) Episodes of hospital admission (that is, any admission involving an overnight stay).
g) Episodes of permanent institutionalisation (that is, permanent move to any care setting other than the subject’s own home,
where paid staff are available to provide care if needed at any time during the day or night).
h) Burden of the carer, as assessed by the Modified Caregiver Strain Index (MCSI) [29].
i) Mortality.
ADL, activities of daily living; IADL, instrumental activities of daily living; MCSI, Modified Caregiver Strain Index; SPPB, short physical performance battery.
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The main aim of the economic assessment is to estimate
the incremental cost-effectiveness ratio of the multi-modal
intervention in frail and pre-frail subjects aged ≥70 years
with type 2 diabetes in comparison with usual best clinical
practice. Three types of cost will be assessed through a
comparative analysis of the alternative courses of action in
terms of both their financial costs and their health out-
comes: 1) direct health care costs, these costs are related
to in-subject and out-subject treatment, and medicines;
2) formal care (mainly social services) costs, this includes
those services that involve public or private funding, in-
cluding the use of a day centre, nursing home, residential
care, home support services, and personal alarm system;
and 3) informal care costs, informal support includes the
different types of non-paid support provided by relatives
and friends as a result of the subject’s disability.
Safety assessments
All co-existing diseases or conditions will be treated in
accordance with prevailing medical practice. All medica-
tions (prescription and over-the-counter) that started
before screening may be continued during the study and
will be recorded as concomitant therapy on the electronic
case report form (eCRF). Medications for any conditions
that may arise after screening, or for worsening of an
existing condition, will be allowed and recorded on the
eCRF; the condition will be reported as an adverse event.
Standard safety data on adverse drug reactions will be col-
lected and reported.
Power and sample size
The sample size per group (intervention and usual care
group) will be 859 subjects. This sample size has been cal-
culated according to the following assumptions: a yearly in-
cidence of functional impairment in frail/pre-frail subjects(main variable) of 30% [30], accumulated incidence of
functional impairment in 2 years of intervention of 51%
(assuming a constant 30% incidence rate year on year), an
intervention effect size of 20%, a z statistic to compare the
proportions of dichotomous variables (as the statistical
test), a two-tailed α = 0.05, a two-tailed 1-β = 0.8, an intra-
cluster coefficient correlation of 0.05, an average cluster
size of 15, and a coefficient of variation cluster size of 0.25
[31,32]. Assuming a 20% loss of subjects during follow-up,
the final sample size will be 1,718 subjects.
Statistical analysis
The primary analysis will compare the odds of developing
functional impairment in the intervention group with the
usual care group, controlling for baseline function, using a
hierarchical logistic regression model with subjects nested
within trial sites. This will be an intention-to-treat analysis
controlling for subject characteristics, such as subject age,
gender, and comorbidities. The groups will be compared in
terms of odds ratios and relative risks.
Secondary outcome variables include: 1) quality of life
as measured by the quality of life measurement tool EQ-
5D-5 L (EuroQoL, Rotterdam, Netherlands), which will be
used in the economic evaluation; 2) hospital admission,
mortality, and permanent institutionalisation, which will
be investigated using hierarchical logistic regression
models, and the results summarised using odds ratios
and relative risks. If there are multiple outcomes per
subject (for example hospital admission), Poisson re-
gression may be used. Hierarchical survival analysis may
also be used to model the time to first event; 3) carer
burden and quality of life, which will be addressed using
hierarchical regression models; and 4) validation of the
Audit of Diabetes-Dependent Quality of Life (ADDQoL)
senior scale [33], including measuring internal consistency
(using Cronbach’s alpha) and establishing convergent and
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expected and not expected to be related with ADDQoL
senior and ADDQoL senior scores). Floor and ceiling ef-
fects will be investigated. Correlation analysis will be
conducted to identify whether the ADDQoL senior scale
correlates with the other measures of function used in this
study. Test re-test reliability will also be estimated (the
ADDQoL senior will be administered at weeks 0, 26, 52,
78, and 104).
All analyses, except for the economic assessment, will
be run by team members at Cardiff University in collabor-
ation with the study and sub-study teams. The economic
analysis will be performed by team members from Univer-
sidad Castilla-La Mancha (Ciudad Real, Spain). Standard
imputation methods (for example mean value imputation,
last observation carried forward) will be used to impute
missing data depending on the pattern of missing data.
Dropout due to death is a possibility in this study popula-
tion. A sensitivity analysis will be run in which dropouts
due to death will be assigned the minimum function score.
Joint modelling of function and dropout due to death will
also be explored. A causal adjusted complier analysis will
be used to estimate the treatment effect observed in those
subjects who complied with the intervention. Survival
analysis naturally deals with censoring, which will help
minimise the effect of dropout in the secondary analyses.
No interim analysis is planned and is not accounted for in
the sample size calculation. An ethics independent exter-
nal advisory committee will be formed and will meet at
least three times during the course of the study to evaluate
its progress, the safety data, the critical efficacy endpoints,
and will make any recommendations to the sponsor and
the steering committee whether to continue, modify, or
stop the study.
Discussion
The rapid increase in the number of older people com-
bined with the high prevalence of diabetes in ageing
populations has created an urgent need for effective in-
terventions to prevent or delay the onset of frailty and
functional decline in older people. The MID-Frail study
will address the lack of intervention studies in older
people with diabetes by examining a comprehensive,
multi-modal intervention designed to reduce functional
decline and improve quality of life.
It is estimated that if the MID-Frail intervention is
successful in reducing disability and functional decline,
700,000 fewer cases of disability will be reported every
year, accompanied by health care savings of more than 3
billion euros per year across the EU. The MID-Frail nutri-
tional and educational programme is intended to prevent
loss of muscle protein and ensure optimal nutritional sta-
tus, to minimise the risk of hypoglycaemia, and assist in
maintaining functional status. Investigators will be guidedon how to prepare each session and how to maximise par-
ticipants’ enjoyment and benefits through interaction. In-
dividual nutritional goals will be set for each subject and
there will be a focus on behavioural change. The specific
dietary needs of older people will be emphasised and the
programme will be tailored in each country to take into
account the influence local social and cultural norms have
on diet.
The study will be randomised using the cluster method;
this is necessary because the education and the exercise
programmes will be done in groups, and this will also
avoid or control for contamination bias. The MID-Frail
study will run for 4 years with a 2-year intervention. We
will capitalise on the long duration of the study and the
large number of subjects involved by carrying out several
sub-studies, which will run concurrently with the main
study and will evaluate complementary research ques-
tions: 1) the characteristics of skeletal muscle and adjacent
tissues will be investigated by sonoelastography at the be-
ginning and at the end of the intervention (Sartrain Sub-
study); 2) exercise-induced, short- and long-term changes
in muscle power output, balance, and gait will be stud-
ied as mediators of the final response on function
(MID-POW Sub-study); 3) kinetic and kinematic move-
ment data will be analysed (Sensole Sub-study); 4) the
metabolic profile of frail/sarcopenic older subjects with
diabetes will be characterised and changes in these
parameters following the intervention will be profiled
(MetaboFrail Sub-study); and 5) polymorphisms of three
genes (Pro259Arg-TCN2 gene; ACE I/D-ACE gene, and
e2/e3/e4-Apo E gene) will be determined to establish
their predictive value for the development of disability
and response to treatment (GeneFrail Sub-study).
The MID-Frail study will provide evidence on the clin-
ical, functional, social, and economic impact of a multi-
modal approach in frail and pre-frail older people with
diabetes.Trial status
The trial is currently being set up.Additional files
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Abbreviations
1RM: One-repetition maximum; ADDQoL: Audit of Diabetes-Dependent Qual-
ity of Life; ADL: Activities of daily living; BMI: Body mass index; CES-D: Center
for Epidemiologic Studies Depression; eCRF: Electronic case report form;
EU: European Union; HDL: High-density lipoprotein; IADL: Instrumental
activities of daily living; MCSI: Modified Caregiver Strain Index; MID-
Frail: Multi-modal intervention in diabetes in frailty; MMSE: Mini Mental State
Examination; NYHA: New York Heart Association; SPPB: Short physical
performance battery.
Rodríguez-Mañas et al. Trials 2014, 15:34 Page 8 of 9
http://www.trialsjournal.com/content/15/1/34Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LRM participated in the conception, design, and writing of the study. AJB
outlined the statistical analysis and performed the sample size calculations.
MK provided input on the statistical analysis. AZ designed the educational
intervention. MI designed the exercise programme. OL participated in the
design of the study. TCH participated in the design and writing of the study.
AJS participated in the conception, design, and writing of the study. All
authors read and approved the final manuscript.
Acknowledgements
The authors thank the University of Ulm (Ulm, Germany) for helping with
administrative tasks. The MID-Frail consortium comprises the following
organisations: Hospital Universitario de Getafe (Getafe, Spain); Institute of
Diabetes for Older People (Luton, UK); Cardiff University (Cardiff, UK); Igen
Biotech (Madrid, Spain); Centre Hospitalier Universitaire de Bordeaux
(Bordeaux, France); HEXABIO, University of Naples (Naples, Italy); Hôpital La
Grave-Casselardit (Toulouse, France); Agaplesion Bethesda Krankenhaus
(Stuttgart, Germany); Ghent University (Ghent, Belgium); Universidad de
Castilla-La Mancha (Ciudad Real, Spain); Charles University (Prague, Czech
Republic); Consorcio de Apoyo a la Investigación Biomédica en Red
(CAIBER, Madrid, Spain; participation withdrawn in June 2012); Niche
Science and Technology (Richmond-upon-Thames, UK); Centro
Medicinadell’Invecchiamento, Università Cattolica Sacro Cuore (Rome, Italy);
and Vrije Universiteit Brussel (Brussels, Belgium). This study was funded by
the European Commission Seventh Framework Programme. Dr Severina
Moreira and Dr Justin Cook from Niche Science and Technology, a member
of the MID-Frail Study consortium, provided writing and editorial support for
the development of this manuscript.
Author details
1Division of Geriatrics, Hospital Universitario de Getafe, Carretera de Toledo
Km 12.5, 28905, Getafe, Spain. 2Fundación para la Investigación Biomédica,
Hospital Universitario de Getafe, Carretera de Toledo Km 12.5 28905, Getafe,
Spain. 3Institute of Primary Care and Public Health, School of Medicine,
Cardiff University and Memory Team, Cardiff and Vale University Health
Board, Cardiff CF14 4YS, UK. 4Institute of Translation, Innovation,
Methodology and Engagement (TIME), South East Wales Trials Unit, School
of Medicine, Cardiff University, Cardiff CF14 4XN, UK. 5University of Ulm,
Institue of Epidemiology, Albert-Einstein-Allee 41, 89081 Ulm, Germany.
6Department of Health Sciences, Public University of Navarre, Campus of
Tudela 31500 Tudela, Spain. 7Niche Science & Technology, Unit 26, Falstaff
House, Bardolph Road, Richmond, TW9 2LH, UK. 8Institute of Diabetes for
Older People (IDOP), University of Bedfordshire, Putteridge Bury Campus,
Hitchin Road, Luton, Bedfordshire LU2 8LE, UK.
Received: 24 April 2013 Accepted: 11 December 2013
Published: 24 January 2014
References
1. Sinclair AJ: Towards a minimum data set for intervention studies in type
2 diabetes in older people. J Nutr Health Aging 2007, 11:289–293.
2. Sinclair AJ, Conroy SP, Bayer AJ: Impact of diabetes on physical function in
older people. Diabetes Care 2008, 31:233–235.
3. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J,
Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health
Study Collaborative Research Group: Frailty in older adults: evidence for a
phenotype. J Gerontol A Biol Sci Med Sci 2001, 56:M146–M156.
4. Oliva J, Lobo F, Molina B, Monereo S: Direct health care costs of diabetic
patients in Spain. Diabetes Care 2004, 27:2616–2621.
5. Volpato S, Maraldi C, Fellin R: Type 2 diabetes and risk for functional
decline and disability in older persons. Curr Diabetes Rev 2010, 6:134–143.
6. Lu F-P, Lin K-P, Kuo H-K: Diabetes and the risk of multi-system aging phe-
notypes: a systematic review and meta-analysis. PLoS One 2009, 4:e4144.
7. Laiteerapong N, Karter AJ, Liu JY, Moffet HH, Sudore R, Schillinger D, John
PM, Huang ES: Correlates of quality of life in older adults with diabetes:
the diabetes & aging study. Diabetes Care 2011, 34:1749–1753.
8. Rosso AL, Eaton CB, Wallace R, Gold R, Curb JD, Stefanick ML, Ockene JK,
Michael YL: Combined impact of geriatric syndromes andcardiometabolic diseases on measures of functional impairment.
J Gerontol A Biol Sci Med Sci 2011, 66A:349–354.
9. Rodriguez-Manas L: A call for action in diabetes care for older people.
Diabet Med 2011, 28:757–758.
10. Ibañez J, Izquierdo M, Argüelles I, Forga L, Larrión JL, García-Unciti M, Idoate
F, Gorostiaga EM: Twice-weekly progressive resistance training decreases
abdominal fat and improves insulin sensitivity in older men with type 2
diabetes. Diabetes Care 2005, 28:662–667.
11. Cadore EL, Rodríguez-Mañas L, Sinclair A, Izquierdo M: Effects of different
exercise interventions on risk of falls, gait ability and balance in
physically frail older adults: a systematic review. Rejuvenation Res 2013,
16:105–114.
12. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC,
Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth
S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald
WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med
2008, 358:2545–2559.
13. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse
JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm
RH Jr, Byington RP, Rosenberg YD, Friedewald WT: Long-term effects of in-
tensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011,
364:818–828.
14. Look AHEAD Research Group, Wing RR: Long-term effects of a lifestyle
intervention on weight and cardiovascular risk factors in individuals with
type 2 diabetes mellitus: four-year results of the look AHEAD trial.
Arch Intern Med 2010, 170:1566–1575.
15. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark
JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt
JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES,
Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE,
Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, et al: Car-
diovascular effects of intensive lifestyle intervention in type 2 diabetes.
N Engl J Med 2013, 369:145–154.
16. MID-Frail. http://www.midfrail-study.org.
17. Mahoney FI, Barthel DW: Functional evaluation: the barthel index.
Md State Med J 1965, 14:61–65.
18. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB: Lower-
extremity function in persons over the age of 70 years as a predictor of
subsequent disability. N Engl J Med 1995, 332:556–561.
19. Folstein MF, Folstein S, McHugh PR: “Mini-mental state”: a practical
method for grading the cognitive state of patients for the clinician.
J Psych Res 1975, 12:189–198.
20. The Criteria Committee of the New York Heart Association: Nomenclature
and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th
edition. Boston, MA: Little, Brown & Co; 1994:253–256.
21. Riskowski JL, Hagedorn TJ, Dufour AB, Hannan MT: Functional foot
symmetry and its relation to lower extremity physical performance in
older adults: the Framingham foot study. J Biomech 2012, 45:1796–1802.
22. Hahn S, Puffer S, Torgerson DJ, Watson J: Methodological bias in cluster
randomised trials. BMC Med Res Methodol 2005, 5:10.
23. Izquierdo M, Häkkinen K, Ibañez J, Garrues M, Antón A, Zúñiga A, Larrión JL,
Gorostiaga EM: Effects of strength training on muscle power and serum
hormones in middle-aged and older men. J Appl Physiol 2001, 90:1497–1507.
24. Braun AK, Kubiak T, Kuntsche J, Meier-Höfig M, Müller UA, Feucht I, Zeyfang
A: SGS: a structured treatment and teaching programme for older pa-
tients with diabetes mellitus — a prospective randomised controlled
multi-centre trial. Age Ageing 2009, 38:390–396.
25. Zeyfang A, Berndt S, Aurnhammer G, Nikolaus T, Oster P, Bahrmann A: A
short easy test can detect ability for autonomous insulin injection by the
elderly with diabetes mellitus. J Am Med Dir Assoc 2012, 13:81. e15–18.
26. Kwon S, Perera S, Pahor M, Katula JA, King AC, Groessl EJ, Studenski SA: What
is a meaningful change in physical performance? findings from a clinical
trial in older adults (the LIFE-P study). J Nutr Health Aging 2009, 13:538–544.
27. Lawton MP, Brody EM: Assessment of older people: self-maintaining and
instrumental activities of daily living. Gerontologist 1969, 9:179–186.
28. EuroQol Group. http://www.euroqol.org.
29. Sinclair AJ, Armes DG, Randhawa G, Bayer AJ: Caring for older adults with
diabetes mellitus: characteristics of carers and their prime roles and
responsibilities. Diabet Med 2010, 27:1055–1059.
30. LIFE Study Investigators, Pahor M, Blair SN, Espeland M, Fielding R, Gill TM,
Guralnik JM, Hadley EC, King AC, Kritchevsky SB, Maraldi C, Miller ME,
Rodríguez-Mañas et al. Trials 2014, 15:34 Page 9 of 9
http://www.trialsjournal.com/content/15/1/34Newman AB, Rejeski WJ, Romashkan S, Studenski S: Effects of a physical
activity intervention on measures of physical performance: results of the
lifestyle interventions and independence for Elders Pilot (LIFE-P) study.
J Gerontol A Biol Sci Med Sci 2006, 61:1157–1165.
31. Elridge SM, Ashby D, Kerry S: Sample size for cluster randomized trials:
effect of coefficient of variation of cluster size and analysis method. Int J
Epidemiol 2006, 35:1292–1300.
32. Voigt-Radloff S, Schochat T, Heiss HW: Controlled trials on the efficacy of
occupational therapy with elderly: part I: research question, search
strategy and methodological quality of trials. Z Gerontol Geriatr 2004,
37:444–449.
33. Speight J, Sinclair AJ, Browne JL, Woodcock A, Bradley C: Assessing the
impact of diabetes on the quality of life of older adults living in a care
home: validation of the ADDQoL Senior. Diabet Med 2013, 30:74–80.
doi:10.1186/1745-6215-15-34
Cite this article as: Rodríguez-Mañas et al.: An evaluation of the
effectiveness of a multi-modal intervention in frail and pre-frail older
people with type 2 diabetes - the MID-Frail study: study protocol for a
randomised controlled trial. Trials 2014 15:34.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
